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Recent findings indicate that the expression of the β-catalytic
subunit of the mitochondrial H+-ATP synthase (β-F1-ATPase)
is depressed in liver, kidney and colon carcinomas, providing
further a bioenergetic signature of cancer that is associated with
patient survival. In the present study, we performed an analysis
of mitochondrial and glycolytic protein markers in breast, gastric
and prostate adenocarcinomas, and in squamous oesophageal and
lung carcinomas. The expression of mitochondrial and glycolytic
markers varied significantly in these carcinomas, when compared
with paired normal tissues, with the exception of prostate cancer.
Overall, the relative expression of β-F1-ATPase was significantly
reduced in breast and gastric adenocarcinomas, as well as in
squamous oesophageal and lung carcinomas, strongly suggesting
that alteration of the bioenergetic function of mitochondria is a
hallmark of these types of cancer.
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INTRODUCTION
The H+-ATP synthase is the mitochondrial protein complex
responsible for harnessing cellular ATP [1]. Efficient execution
of programmed cell death also requires the activity and molecular
components of the H+-ATP synthase [2–4]. Recently, decreased
expression of the β-catalytic subunit of the H+-ATP synthase
(β-F1-ATPase or βF1 in ratios) has been demonstrated in liver,
kidney and colon carcinomas [5]. These findings provide molec-
ular evidence that support an altered bioenergetic function of mito-
chondria in these types of cancer [5], in agreement with the
Warburg hypothesis [6]. In this regard, we defined a bioenergetic
cellular index (BEC index) that could be used to estimate tumour
status [5]. The BEC index takes into consideration the expression
level of a bioenergetic marker of mitochondria relative to a
cellular glycolytic marker, which can be easily determined
in tissue biopsies by immunohistochemical or immunoblotting
analysis [5]. The down-regulation of the β-F1-ATPase protein
and assessment of the BEC index in colon carcinomas was shown
further to have prognostic value in assessing the clinical outcome
of patients with early-stage disease [5].
The possible impairment of the bioenergetic function of
mitochondria in other human tumours has not been explored.
In the present study, we have examined the expression of β-F1-
ATPase as protein marker of oxidative phosphorylation and of
hsp60 (heat-shock protein 60) as marker of structural mito-
chondrial protein, in combination with two markers of the glyco-
lytic pathway [GAPDH (glyceraldehyde-3-phosphate dehydro-
genase) and PK (pyruvate kinase)], in randomly selected biopsies
of primary breast, gastric and prostate adenocarcinomas, and in
squamous lung and oesophageal carcinomas, as well as in the
normal tissue biopsies of the same patients. We show that
the expression of β-F1-ATPase, either alone or in combination
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with mitochondrial and glycolytic markers (as defined by the
BEC index), is significantly diminished in breast, gastric, lung
and oesophageal cancers. Overall, the findings suggest that an
impaired bioenergetic function of mitochondria is a hallmark of
carcinogenesis in these human tissues. Furthermore, we suggest
that the bioenergetic signature could provide a convenient tool
for the diagnosis of patients bearing breast, lung, gastric and
oesophageal cancers.
EXPERIMENTAL
Patient specimens
Frozen tissue sections of 17 µm thickness, obtained from human
biopsies of untreated patients with primary ductal invasive breast
adenocarcinomas, gastric and prostate adenocarcinomas, and
squamous oesophageal and lung carcinomas, were obtained
from the Banco de Tejidos y Tumores, IDIBAPS (Instituto de
Investigaciones Biome´dicas Augusto Pi y Sun˜er), Hospital Clinic,
Barcelona, Spain. The tissue sections of the tumour and normal
tissue of each patient were analysed previously by an expert
pathologist. All tissue samples used in the present study were
anonymized and received in a coded form to protect patient
confidentiality under IRB (Internal Review Board) approval.
Protein extraction
Approx. 20 tissue sections were extracted in 300 µl of
50 mM Tris/HCl, pH 8, containing 150 mM NaCl, 0.02% (w/v)
sodium azide, 0.1% (w/v) SDS, 1% (v/v) Nonidet P40,
0.5% (w/v) sodium deoxycholate, 1 µg/ml aprotinin, 1 µg/ml
leupeptin, 1 µg/ml antitripsin, 0.4 mM EDTA, 10 mM NaF and
0.75 mM PMSF at 4 ◦C for 30 min. After protein extraction, the
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Figure 1 Expression of mitochondrial and glycolytic marker proteins in human tumours
Protein samples from normal (N) and tumour (T) biopsies from the same patient were fractionated by SDS/PAGE (10 % or 15 % gels) and then blotted with the corresponding antibodies. Markers
of oxidative phosphorylation (β-F1-ATPase) and structural function (hsp60) of the mitochondria and of the glycolytic pathway (GAPDH and PK) were studied. The electrophoretic migration (kDa) of
each marker is shown on the right-hand side of the Figure. For illustration purposes, the results of two patients are shown for each type of carcinoma. The histograms show the means +− S.E.M.
of the cellular content of each marker as determined by densitometric analysis (arbitrary units) in normal (open bars) and tumour (closed bars) biopsies. The βF1/hsp60 ratio and BEC index
([βF1/hsp60]/GAPDH ratio) provide a normalized expression level of β-F1-ATPase for each sample. *P < 0.05 when compared with normal tissue by Student’s t test. (A) Breast (n = 10), gastric
(n = 10) and prostate (n = 9) adenocarcinomas. (B) Squamous lung (n = 9) and oesophageal (n = 6) carcinomas.
samples were centrifuged (15000 g) at 4 ◦C for 25 min. The
protein concentration in the supernatants was determined with the
Bradford reagent (Bio-Rad Protein Assay) using BSA as standard.
Aliquots of the supernatants were stored at − 80 ◦C until used.
Western blotting
Western blots for paired normal and tumour samples of the same
patient were run in the same gel. Samples (15 or 30 µg of protein)
were subjected to SDS/PAGE (10% or 15% gels) followed by
immunoblot analysis [7] using the appropriate dilution of various
antisera. The antibodies used in the present study included:
rabbit anti-β-F1-ATPase at 1:20000 dilution [5]; mouse mono-
clonal anti-hsp60 (SPA 807; Stressgene, Victoria, Canada) at
1:2000 dilution; goat polyclonal anti-(muscle PK) at 1:2000 dilu-
tion and mouse monoclonal anti-GAPDH at 1:10000 dilution,
both from Abcam (Cambridge, U.K.). Secondary horseradish-
peroxidase-conjugated goat anti-rabbit, anti-mouse or rabbit anti-
goat antibodies (1:3000 dilution) were used for detection, which
was accomplished using an enhanced chemiluminescence detec-
tion method (ECL®; Amersham Biosciences). Quantification of
the intensity of the immunoreactive bands (arbitrary units) was
accomplished using a Kodak DC120 Zoom digital camera and the
Kodak 1D Image Analysis Software for Windows. To calculate
the normalized expression level of β-F1-ATPase, the band in-
tensity of β-F1-ATPase was divided by the band intensity of
hsp60 assayed for the same sample and in the same membrane.
To calculate the BEC index [5], the aforementioned ratio was
normalized relative to the band intensity of GAPDH. Statistical
analysis was performed using Student’s t test for paired samples.
RESULTS
Breast adenocarcinomas
The analysis of the expression level of mitochondrial and glyco-
lytic marker proteins in ten primary breast ductal invasive
adenocarcinomas and in their corresponding paired normal tissue
biopsies revealed that the levels of β-F1-ATPase protein were
reduced in seven of the tumours analysed (Figure 1A). In contrast,
the expression of mitochondrial hsp60 was increased in all
of the tumours analysed (Figure 1A). The glycolytic GAPDH and
PK markers were elevated in 80% and 100% of the tumours
analysed respectively (Figure 1A). The normalized expression
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level of β-F1-ATPase, as assessed by the βF1/hsp60 ratio, showed
a significant reduction in breast adenocarcinomas when compared
with normal breast samples (Figure 1A). Likewise, the BEC index
([βF1/hsp60]/GAPDH ratio) showed that breast cancer samples
have a BEC index much lower than that in the normal breast tissue
(Figure 1A).
Gastric adenocarcinomas
The analysis of the expression level of β-F1-ATPase in ten gastric
adenocarcinomas and in their corresponding paired normal tissue
samples revealed that the marker was significantly reduced in
90% of the tumours analysed (Figure 1A). In contrast, the
expression of the mitochondrial hsp60 was not affected in gastric
adenocarcinomas when compared with normal tissues (Fig-
ure 1A). A slight, marginally significant increase was observed
in the expression of GAPDH, whereas PK was not significantly
affected in adenocarcinomas of the stomach (Figure 1A). The
expression of β-F1-ATPase relative to that of hsp60 revealed
a significant decrease of this ratio in all the tumours when
compared with normal tissue (Figure 1A). Consistent with the
above findings, the BEC index showed a significant decrease in
the adenocarcinomas (Figure 1A).
Prostate adenocarcinomas
No significant differences were observed in the expression level
of β-F1-ATPase and hsp60 in nine prostate adenocarcinomas
when compared with their corresponding normal tissue controls
(Figure 1A). Likewise, the expression of GAPDH and PK was not
significantly affected in prostate cancer (Figure 1A). Therefore
the normalized expression levels of β-F1-ATPase and BEC index
were not altered in prostate adenocarcinomas (Figure 1A).
Squamous carcinomas of the lung
The expression of β-F1-ATPase was not significantly altered in the
nine squamous lung carcinomas analysed when compared with
normal tissue (Figure 1B). However, the expression of hsp60
was significantly increased in the tumours (Figure 1B). An
increased expression of GAPDH was also observed in all the
carcinomas when compared with normal samples (Figure 1B).
In contrast, the expression of PK was not significantly altered in
squamous lung carcinomas (Figure 1B). The expression of β-F1-
ATPase normalized to hsp60 revealed a significant reduction in
the tumours when compared with the normal tissue (Figure 1B).
Consistent with the above findings, the BEC index revealed a
significant decrease in squamous lung carcinomas when compared
with normal lung (Figure 1B).
Squamous carcinomas of the oesophagus
Five of the six squamous oesophageal carcinomas analysed
showed a significant reduction in the expression of β-F1-ATPase
when compared with its normal paired sample (Figure 1B).
Interestingly, the expression of the mitochondrial hsp60 marker
was significantly increased in the carcinomas when compared
with the normal tissue (Figure 1B). The expression of GAPDH
and PK was not significantly altered in oesophageal carcinomas
(Figure 1B). Consistent with these findings, both the normalized
expression level of β-F1-ATPase (βF1/hsp60 ratio) and the
BEC-index revealed a significant decrease in the carcinomas
(Figure 1B).
DISCUSSION
Large-scale genomic [8,9] and proteomic [10] techniques have
allowed the analysis of the expression pattern of the genes and
proteins that are associated with the phenotype of a particular
type of tumour, providing its so-called ‘cancer signature’ [11,12].
We have recently shown that the mitochondrial and glycolytic
phenotypes of colon carcinomas provide a bioenergetic signature
of cancer that has prognostic value in clinical practice [5]. In
the present paper, we have analysed the expression of a set of
mitochondrial and glycolytic markers in other types of common
human carcinomas to explore whether or not the alteration of
the bioenergetic signature is a generalized condition of cancer.
We show that, with the exception of prostate adenocarcinomas,
the bioenergetic signature of cancer, as assessed by the absol-
ute expression level of β-F1-ATPase (breast, oesophagus and
stomach) or by its relative expression when considering other
mitochondrial and cellular proteins (lung, breast, oesophagus
and stomach), provides a molecular marker of carcinogenesis.
Although the expression level of a protein marker does not
necessarily reflect the cellular activity of the protein, the findings
reported in the present paper, in addition to previous observations
in liver, kidney and colon carcinomas [5], strongly suggest that
altered bioenergetic function of mitochondria is a hallmark of
carcinogenesis, as was hypothesized by Warburg almost 80 years
ago [6]. The probable metabolic consequence of this impairment
is the increased production of cellular ATP by enhanced rates of
glycolysis. In this regard, we observed that, with the exception
of prostate and oesophageal cancer, the GAPDH marker of the
glycolytic pathway is increased in breast, gastric, lung, kidney
and colon tumours (Figures 1A and 1B; and [5]). However, in
those tumours where PK has been determined (the present study),
we only observed a significant increase in the marker in breast
tumours (Figures 1A and 1B). This finding could suggest that, in
gastric and lung carcinomas, the relative cellular content and/or
the regulation of the activity of PK are sufficient to channel
through glycolysis the increase in carbon skeletons supplied by
an augmented expression of GAPDH. In this regard, it has been
documented that the induction of glycolytic genes by glucose is
specific for some genes and not all of those that are induced are
activated to the same extent and with the same kinetics [13].
The glycolytic and mitochondrial proteome of the different
mammalian cell types differ substantially, both in terms of the re-
lative expression level of the expressed proteins and in the expres-
sion of cell-type-specific isoforms, reflecting the relative
relevance of the two energy-production pathways and the variable
energetic demands of each cell type. In this regard, we observed a
variable tissue response in the expression of the structural hsp60
marker of the mitochondria as a result of carcinogenesis. This
finding is consistent with the de-regulation by carcinogenesis
of the cell-type-specific programmes that control mitochondrial
biogenesis and function in different mammalian tissues [14–17].
In this regard, the relative cellular increase in hsp60 expression
observed in breast, lung and oesophageal cancer could suggest
an activation of the programme of mitochondrial proliferation in
these tumours as an attempt to compensate for the restrained
cellular production of ATP by oxidative phosphorylation. In
contrast, the lack of increase of hsp60 observed in gastric
adenocarcinomas (Figure 1A), as well as in kidney and colon
cancer [5], suggests that, although the functional differentiation
[14,18,19] of the organelle is affected, in these types of cancer,
there is no activation of mitochondrial proliferation. As recently
discussed, the reduction of bioenergetic, structural and genetic
markers of mitochondria observed in rat [20] and human hepato-
carcinomas [21] is a paradigm of repression of the mechanisms
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that regulate mitochondrial proliferation in the liver. Altogether,
it appears that carcinogenesis differentially affects the phenotype
of mitochondria in a tissue-specific manner, except in prostate
cancer. In any case, we suggest that the BEC index could provide
a convenient tool for the diagnosis of cancer patients bearing
breast, lung, gastric and oesophageal tumours. The usefulness of
the bioenergetic signature as a clinical marker should be explored
in the near future in these types of cancer.
The mechanism by which the expression of β-F1-ATPase is
repressed in human cancers is not known. The expression of β-F1-
ATPase mRNA in human tumours of the brain, colon, eye, kidney,
liver, lung, lymph nodes, mammary gland, placenta, prostate, skin,
testis and uterus is up-regulated (P < 0.05) when compared with
the normal tissue, as assessed by virtual Northern blotting using
publicly available databases [22]. These findings strongly suggest
that the control of β-F1-ATPase expression in cancer is exerted
at the level of translation of its mRNA. Indeed, translational
control of β-F1-ATPase expression has been documented in the
liver during development [23–25], in rat hepatomas [7] and
in the tissue-specific expression of this protein in mammalian
tissues [25]. The mechanisms that control β-F1-ATPase mRNA
translation in mammalian cells are complex [25–28]. However,
repression of β-F1-ATPase mRNA translation is associated with
increased expression and/or activity of specific β-F1-ATPase
mRNA-binding proteins that are regulated during development
[25], in a tissue-specific manner [25] and in oncogenesis [7].
The molecular identification of these binding proteins, as well
as the factors that regulate their RNA-binding activity should be
targets of future cancer investigations. Likewise, the finding that
β-F1-ATPase expression is repressed in most tumours suggests
that further efforts are required to understand the mechanistic
contribution of the mitochondrial H+-ATP synthase in cancer
progression.
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